{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:58:39Z","timestamp":1776283119433,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Suzhou Health Talents Training Project","award":["GSWS2019002"],"award-info":[{"award-number":["GSWS2019002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is one of the most common neurological diseases around the world and calcitonin gene-related peptide (CGRP) plays an important role in its pathophysiology. Therefore, in the present study, we evaluated the efficacy of monoclonal antibodies blocking the CGRP ligand or receptor in episodic and chronic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of our study is implementing a meta-analysis to systematically evaluate the efficacy and safety of eptinezumab for the treatment of migraine compared with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      We searched the Medline, Embase, Cochrane Library and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                      for randomized controlled trials (RCTs) which were performed to evaluate eptinezumab versus placebo for migraine up to September 2020. The data was assessed by Review Manager 5.3 software. The risk ratio (RR) and standard mean difference (SMD) were analyzed using dichotomous outcomes and continuous outcomes respectively with a random effect model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      We collected 2739 patients from 4 RCTs: the primary endpoint of efficacy was the change from baseline to week 12 in mean monthly migraine days (MMDs). We found that eptinezumab (30\u2009mg, 100\u2009mg, 300\u2009mg) led to a significant reduction in MMDs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001) during 12\u2009weeks compared with placebo, especially with 300\u2009mg. For the safety, we compared and concluded the treatment emergent adverse events (TEAEs) of the 4 RCTs. This indicated no evident statistical difference between eptinezumab and placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the present study, we found that eptinezumab is safe and has significant efficacy in the treatment of migraine, especially the dose of 300\u2009mg.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-021-01220-y","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T13:03:05Z","timestamp":1615035785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Zeya","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0845","authenticated-orcid":false,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"publisher","first-page":"g1416","DOI":"10.1136\/bmj.g1416","volume":"348","author":"TJ Schwedt","year":"2014","unstructured":"Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416","journal-title":"BMJ"},{"issue":"9","key":"1220_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache, S","year":"2013","unstructured":"Headache Classification Committee of the International Headache, S (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629\u2013808","journal-title":"Cephalalgia"},{"issue":"1","key":"1220_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/JOM.0b013e3181c1dc56","volume":"52","author":"WF Stewart","year":"2010","unstructured":"Stewart WF et al (2010) Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 52(1):8\u201314","journal-title":"J Occup Environ Med"},{"issue":"11","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"Collaborators, G.B.D.H","year":"2018","unstructured":"Collaborators, G.B.D.H (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976","journal-title":"Lancet Neurol"},{"key":"1220_CR5","doi-asserted-by":"crossref","unstructured":"Lipton, R.B. and S.D. Silberstein, Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache, 2015. 55 Suppl 2: p. 103\u2013122; quiz 123-6","DOI":"10.1111\/head.12505_2"},{"issue":"4","key":"1220_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","volume":"23","author":"G Lambru","year":"2018","unstructured":"Lambru G et al (2018) Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs 23(4):301\u2013318","journal-title":"Expert Opin Emerg Drugs"},{"issue":"Suppl 4","key":"1220_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221\u2013235","journal-title":"Headache"},{"issue":"23","key":"1220_CR8","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381(23):2230\u20132241","journal-title":"N Engl J Med"},{"issue":"7","key":"1220_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894\u20131904","journal-title":"Brain"},{"issue":"Suppl 3","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache 58(Suppl 3):238\u2013275","journal-title":"Headache"},{"issue":"11","key":"1220_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1474-4422(14)70228-5","volume":"13","author":"HC Diener","year":"2014","unstructured":"Diener HC (2014) CGRP as a new target in prevention and treatment of migraine. Lancet Neurol 13(11):1065\u20131067","journal-title":"Lancet Neurol"},{"issue":"2 Suppl","key":"1220_CR12","first-page":"S23","volume":"25","author":"GL Peters","year":"2019","unstructured":"Peters GL (2019) Migraine overview and summary of current and emerging treatment options. Am J Manag Care 25(2 Suppl):S23\u2013S34","journal-title":"Am J Manag Care"},{"issue":"11","key":"1220_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1358\/dot.2019.55.11.3069864","volume":"55","author":"D Scuteri","year":"2019","unstructured":"Scuteri D et al (2019) Eptinezumab for the treatment of migraine. Drugs Today (Barc) 55(11):695\u2013703","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"1220_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6","journal-title":"J Headache Pain"},{"issue":"1","key":"1220_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-019-1000-5","volume":"20","author":"C Tiseo","year":"2019","unstructured":"Tiseo C et al (2019) How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain 20(1):49","journal-title":"J Headache Pain"},{"issue":"3","key":"1220_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254","journal-title":"Cephalalgia"},{"issue":"11","key":"1220_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100\u20131107","journal-title":"Lancet Neurol"},{"issue":"8","key":"1220_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/head.12907","volume":"56","author":"JT Smith","year":"2016","unstructured":"Smith JT et al (2016) Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. Headache 56(8):1391","journal-title":"Headache"},{"issue":"13","key":"1220_CR19","doi-asserted-by":"publisher","first-page":"E1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):E1365\u2013E1377","journal-title":"Neurology"},{"key":"1220_CR20","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"issue":"2","key":"1220_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ et al (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553\u2013622","journal-title":"Physiol Rev"},{"issue":"9","key":"1220_CR22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu D et al (2019) Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39(9):1164\u20131179","journal-title":"Cephalalgia"},{"key":"1220_CR23","first-page":"105","volume":"59","author":"B Allan","year":"2019","unstructured":"Allan B et al (2019) Prevail: an open-label phase 3 trial to evaluate the safety of eptinezumab administered intravenously in patients with chronic migraine. Headache 59:105","journal-title":"Headache"},{"issue":"6","key":"1220_CR24","first-page":"250","volume":"38","author":"HC Diener","year":"2020","unstructured":"Diener HC (2020) Eptinezumab for the prevention of episodic migraine. Arzneimitteltherapie 38(6):250\u2013251","journal-title":"Arzneimitteltherapie"},{"issue":"12","key":"1220_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","volume":"39","author":"Y Zhu","year":"2018","unstructured":"Zhu Y et al (2018) The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci 39(12):2097\u20132106","journal-title":"Neurol Sci"},{"issue":"5","key":"1220_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40263-020-00715-7","volume":"34","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) Safety and efficacy of Ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs 34(5):463\u2013471","journal-title":"CNS Drugs"},{"key":"1220_CR27","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3389\/fphar.2019.01577","volume":"10","author":"B Gao","year":"2019","unstructured":"Gao B et al (2019) Efficacy and safety of Rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 10:1577","journal-title":"Front Pharmacol"},{"issue":"1","key":"1220_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s10194-020-1085-x","volume":"21","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials. J Headache Pain 21(1):14","journal-title":"J Headache Pain"},{"issue":"7","key":"1220_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A et al (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract 12(7):541\u2013549","journal-title":"Pain Pract"},{"issue":"5","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-021-01220-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T13:03:15Z","timestamp":1615035795000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01220-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01220-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-108533\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}